About Immucare Diagnostics Private Limited
Data last updated:
Immucare Diagnostics Private Limited is a private limited company based in Ernakulam, Kerala, India, a subsidiary of Medgenome Labs Limited. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 11 April 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Ernakulam, under CIN U85300KL2019PTC057597. Its GSTIN is 32AAFCI2433K2ZR (Kerala).
The company has an authorised share capital of ₹11 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors including Suryaprakasam Vedam Lakshmi Ramprasad and Balamaniamma Madathinkal Raghavan Nair.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Door No:16/554 – 3 Near Toyota Showroom Nettoor, Ernakulam, Kerala, India – 682304.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.37 Cr, a decline of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.46 Cr (net margin 61.7%) and EBITDA of ₹1.56 Cr (EBITDA margin 65.9%). Revenue has grown at a compounded annual rate (CAGR) of 20% over three years and 28% over five years.
For more details, the company can be reached via its website immucarelabs.com.
Company details
Contact details
Immucare Diagnostics Private Limited's registered office is in Ernakulam, Kerala. Its website is immucarelabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressDoor No:16/554 – 3 Near Toyota Showroom Nettoor, Ernakulam, Kerala, India – 682304
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
To see the full contact details of Immucare Diagnostics Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activities of Immucare Diagnostics are professional, scientific and technical and hospital and medical care. In detail, this covers scientific research and development and other hospital and medical care activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | |
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
To see the full business activity and turnover split of Immucare Diagnostics Private Limited, buy the company report.
Financials of Immucare Diagnostics Private Limited
FY 2025 filings availableImmucare Diagnostics Private Limited reported revenue of ₹2.37 Cr (down 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 21% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 28%. EBITDA rose 327% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.56 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.46 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 65.9% | ||||
| Net Profit Margin | 61.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Immucare Diagnostics Private Limited, buy the company report.
Board of directors of Immucare Diagnostics Private Limited
Immucare Diagnostics has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Suryaprakasam Vedam Lakshmi Ramprasad Also directs: Medgenome Labs Limited, Green Cross Genetics Lab Private Limited, Genx Diagnostics Limited and 3 more | Director | 26 Mar 2024 | 2 Years 7 Months | Current |
| Balamaniamma Madathinkal Raghavan Nair Also directs: Nextgen Science Media Private Limited, Thinkbio AI India Private Limited, Simisco Biologics Private Limited and 5 more | Director | 11 Apr 2019 | 7 Years 6 Months | Current |
| Surajit Chakrabartty Also directs: Ekavidha Corporate Services Private Limited, Medgenome Labs Limited, Green Cross Genetics Lab Private Limited and 4 more | Director | 25 Jan 2024 | 2 Years 9 Months | Current |
Auditor
Immucare Diagnostics Private Limited is audited by BSR & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BSR & Associates LLP | FY 2023 | 218495 |
Shareholding
The shareholding of Immucare Diagnostics Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Immucare Diagnostics Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Immucare Diagnostics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Immucare Diagnostics Private Limited has 9 MSME Form 1 returns on record between 2022 and 2023, listing 195 overdue payments to 10 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 10)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| CPC Diagnostics Pvt Ltd | |||
| Divine Diagnostics | |||
| J D Diagnostics Pvt Ltd | |||
| Cytogen Lifesciences | |||
| Associated Scientific Company |
To see the full MSME payment records of Immucare Diagnostics Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Immucare Diagnostics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 32AAFCI2433K2ZR | Kerala | Active | 15 May 2021 |
To see the full GST registrations and return filing status of Immucare Diagnostics Private Limited, buy the company report.
Recent activity
Immucare Diagnostics Private Limited has 7 board changes on record since 2019: 3 appointments and 4 cessations. The latest: Surajit Chakrabartty ceased to be Additional Director on 29 Sep 2024.
Frequently asked questions
Immucare Diagnostics is an active private limited company based in Ernakulam, Kerala, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 11 April 2019 (7+ years old) and is registered under CIN U85300KL2019PTC057597.
Immucare Diagnostics has 3 current directors:
- Suryaprakasam Vedam Lakshmi Ramprasad - Director
- Balamaniamma Madathinkal Raghavan Nair - Director
- Surajit Chakrabartty - Director
The latest financial statements of Immucare Diagnostics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Immucare Diagnostics is 32AAFCI2433K2ZR, registered in Kerala.
The CIN (Corporate Identification Number) of Immucare Diagnostics is U85300KL2019PTC057597. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Immucare Diagnostics was incorporated on 11 April 2019, making it 7+ years old. It is registered with the Registrar of Companies, Ernakulam.
Surajit Chakrabartty ceased to be Additional Director on 29 Sep 2024. Suryaprakasam Vedam Lakshmi Ramprasad ceased to be Additional Director on 29 Sep 2024. Suryaprakasam Vedam Lakshmi Ramprasad was appointed as Director on 26 Mar 2024. Immucare Diagnostics has 7 board changes on record in total.
Immucare Diagnostics has 9 MSME Form 1 returns on record between 2022 and 2023, listing 195 overdue payments to 10 micro and small suppliers. The latest return was filed on 19 Dec 2023.
Immucare Diagnostics can be reached through the website immucarelabs.com. Its registered office is in Ernakulam, Kerala, India.
The registered office of Immucare Diagnostics is at Door No:16554 – 3 Near Toyota Showroom Nettoor, Ernakulam, Kerala, India – 682304.
Immucare Diagnostics operates in the healthcare industry, in the diagnostic centers and pathology labs segment.